Human Life CORD Japan

Human Life CORD Japan is a clinical-stage biotechnology company specializing in regenerative medicine through the development of umbilical cord-derived mesenchymal stem cell (UC-MSC) therapies. Founded in 2017 and based in Tokyo, the company leverages a proprietary platform to manufacture high-quality cell products from donated umbilical cords, which are typically discarded as medical waste. Their lead candidate, HLC-001, is currently in Phase 2 clinical trials for the treatment of acute graft-versus-host disease (aGVHD) and Phase 1 for neonatal hypoxic-ischemic encephalopathy. The company operates its own cell processing facility to ensure a stable and standardized supply of its therapeutic candidates. By focusing on neonatal tissues, Human Life CORD Japan aims to provide effective treatments for severe inflammatory and neurological conditions with high unmet medical needs.